{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:47:45Z","timestamp":1791229665942,"version":"4.1.0"},"reference-count":56,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"unspecified","delay-in-days":202,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Psychol. Med."],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S0033291725100652_sec1\">\n\t    <jats:title>Background<\/jats:title>\n\t    <jats:p>There has been debate about the frequency and severity of antidepressant withdrawal effects.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0033291725100652_sec2\" sec-type=\"methods\">\n\t    <jats:title>Methods<\/jats:title>\n\t    <jats:p>We set out to appraise and reanalyze an influential systematic review by Henssler and colleagues that concluded that withdrawal effects are not particularly common and rarely severe. We repeated the meta-analysis, including only studies where data were derived from systematic measures of withdrawal symptoms.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0033291725100652_sec3\" sec-type=\"results\">\n\t    <jats:title>Results<\/jats:title>\n\t    <jats:p>Most data in the Henssler review are derived from pharmaceutical industry\u2013sponsored efficacy studies in which withdrawal was a minor consideration. Shortcomings of the review include the use of spontaneously reported adverse events to estimate withdrawal symptoms, potential misclassification of withdrawal symptoms as relapse, inclusion of data from retrospective case-note studies, short duration of prior antidepressant use, short observation periods, the overlooking of differences between placebo and drug withdrawal effects, and the use of questionable proxies for severe withdrawal. There were also discrepancies and uncertainties in some figures used. In our reanalysis, we included only the five studies that used a systematic and relevant method to assess the incidence of any withdrawal symptom. Prior treatment was short-term (12 weeks or less) in all but one of these. The pooled percentage was 55% (95% confidence interval, CI, 31% to 81%; <jats:italic>N<\/jats:italic>\u00a0=\u00a0601) without subtracting nocebo effects, with high heterogeneity.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0033291725100652_sec4\" sec-type=\"conclusions\">\n\t    <jats:title>Conclusions<\/jats:title>\n\t    <jats:p>Henssler\u2019s review is based on unreliable data and does not provide an adequate basis for the evaluation of antidepressant withdrawal effects. Further good-quality research on antidepressant withdrawal is required.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1017\/s0033291725100652","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T07:01:26Z","timestamp":1753167686000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":10,"title":["Evidence on antidepressant withdrawal: an appraisal and reanalysis of a recent systematic review"],"prefix":"10.1017","volume":"55","author":[{"given":"Joanna","family":"Moncrieff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Hobday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pl\u00f6derl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hengartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janus","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Juul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"S0033291725100652_r9","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1751-7176.2008.00006.x","article-title":"Proactive compared with passive adverse event recognition: Calcium channel blocker-associated edema","volume":"10","author":"Chrysant","year":"2008","journal-title":"Journal of Clinical Hypertension"},{"key":"S0033291725100652_r54","unstructured":"Zhang, M.-M. , Tan, X. , Zheng, Y.-B. , Zeng, N. , Li, Z. , Horowitz, M. A. , \u2026 Li, S.-X. (2024). Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review, 1\u201312. https:\/\/scholar.google.com\/citations?view_op=view_citation&hl=en&citation_for_view=sEcbBuUAAAAJ:uWQEDVKXjbEC"},{"key":"S0033291725100652_r13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.addbeh.2019.01.026","article-title":"Review of authors\u2019 response to a critique by Jauhar and Hayes of \u201ca systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guideline evidence-based?\u201d","volume":"97","author":"Davies","year":"2019b","journal-title":"Addictive Behaviors"},{"key":"S0033291725100652_r24","doi-asserted-by":"crossref","first-page":"l6103","DOI":"10.1136\/bmj.l6103","article-title":"NICE updates antidepressant guidelines to reflect severity and length of withdrawal symptoms","volume":"367","author":"Iacobucci","year":"2019","journal-title":"BMJ"},{"key":"S0033291725100652_r51","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.clinthera.2009.07.006","article-title":"Desvenlafaxine 50 and 100 mg\/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies","volume":"31","author":"Tourian","year":"2009","journal-title":"Clinical Therapeutics"},{"key":"S0033291725100652_r52","article-title":"A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder","volume":"13","author":"Tourian","year":"2011","journal-title":"The Primary Care Companion to CNS Disorders"},{"key":"S0033291725100652_r44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archpsyc.1993.01820130067010","article-title":"Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper","volume":"50","author":"Rickels","year":"1993","journal-title":"Archives of General Psychiatry"},{"key":"S0033291725100652_r26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/JCP.0000000000000100","article-title":"Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg\/d","volume":"34","author":"Khan","year":"2014","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"S0033291725100652_r101","doi-asserted-by":"crossref","DOI":"10.1097\/YIC.0b013e32832fbb5a","article-title":"Discontinuation symptoms and taper\/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder","volume":"24","author":"Montgomery","year":"2009","journal-title":"Int Clin Psychopharmacol"},{"key":"S0033291725100652_r40","doi-asserted-by":"crossref","first-page":"e024537","DOI":"10.1136\/bmjopen-2018-024537","article-title":"Analysis and reporting of adverse events in randomised controlled trials: A review","volume":"9","author":"Phillips","year":"2019","journal-title":"BMJ Open"},{"key":"S0033291725100652_r45","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4088\/JCP.12m07974","article-title":"Efficacy and safety of desvenlafaxine 50 mg\/d for prevention of relapse in major depressive disorder:A randomized controlled trial","volume":"74","author":"Rosenthal","year":"2013","journal-title":"The Journal of Clinical Psychiatry"},{"key":"S0033291725100652_r29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1176\/ajp.118.6.549","article-title":"Withdrawal symptoms following dicontinuation of imipramine therapy","volume":"118","author":"Kramer","year":"1961","journal-title":"The American Journal of Psychiatry"},{"key":"S0033291725100652_r33","first-page":"215","article-title":"Prospective evaluation of antidepressant discontinuation","volume":"24","author":"Mourad","year":"1998","journal-title":"L\u2019Encephale"},{"key":"S0033291725100652_r27","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.4088\/JCP.v67n1115","article-title":"Escitalopram maintenance treatment for prevention of recurrent depression: A randomized, placebo-controlled trial","volume":"67","author":"Kornstein","year":"2006","journal-title":"The Journal of Clinical Psychiatry"},{"key":"S0033291725100652_r39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jad.2005.09.003","article-title":"Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder","volume":"89","author":"Perahia","year":"2005","journal-title":"Journal of Affective Disorders"},{"key":"S0033291725100652_r14","doi-asserted-by":"crossref","first-page":"e41239","DOI":"10.1371\/journal.pone.0041239","article-title":"Reliability of the peer-review process for adverse event rating","volume":"7","author":"Forster","year":"2012","journal-title":"PLoS One"},{"key":"S0033291725100652_r23","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S2215-0366(19)30032-X","article-title":"Tapering of SSRI treatment to mitigate withdrawal symptoms","volume":"6","author":"Horowitz","year":"2019","journal-title":"The Lancet Psychiatry"},{"key":"S0033291725100652_r46","first-page":"192","article-title":"Description of antidepressant withdrawal symptoms in clinical practice guidelines on depression: A systematic review","volume":"27","author":"S\u00f8rensen","year":"2022a","journal-title":"Journal of Affective Disorders"},{"key":"S0033291725100652_r2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1017\/S1461145705005973","article-title":"Prevention of relapse in generalized anxiety disorder by escitalopram treatment","volume":"9","author":"Allgulander","year":"2006","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"S0033291725100652_r15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9260","article-title":"Indirect comparisons of competing interventions","volume":"9","author":"Glenny","year":"2005","journal-title":"Health Technology Assessment"},{"key":"S0033291725100652_r8","unstructured":"Burn, W. , Horowitz, M. , Roycroft, G. , & Taylor, D. (2020). Stopping antidepressants. Stopping Antidepressants Website. https:\/\/www.rcpsych.ac.uk\/mental-health\/treatments-and-wellbeing\/stopping-antidepressants"},{"key":"S0033291725100652_r32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/01.yic.0000137184.64610.c8","article-title":"Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study","volume":"19","author":"Montgomery","year":"2004","journal-title":"International Clinical Psychopharmacology"},{"key":"S0033291725100652_r6","first-page":"146","article-title":"The abrupt discontinuation of fluvoxamine in patients with panic disorder","volume":"54","author":"Black","year":"1993","journal-title":"The Journal of Clinical Psychiatry"},{"key":"S0033291725100652_r48","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/JCP.0b013e318184ff5b","article-title":"Efficacy of agomelatine in generalized anxiety disorder: A randomized, double-blind, placebo-controlled study","volume":"28","author":"Stein","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"S0033291725100652_r18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/1740774511419165","article-title":"Secondary use of randomized controlled trials to evaluate drug safety: A review of methodological considerations","volume":"8","author":"Hammad","year":"2011","journal-title":"Clinical Trials"},{"key":"S0033291725100652_r41","doi-asserted-by":"crossref","first-page":"e000972","DOI":"10.1136\/bmjoq-2020-000972","article-title":"Comparison of active versus passive surveillance adverse event reporting in a paediatric ambulatory chiropractic care setting: A cluster randomised controlled trial","volume":"9","author":"Pohlman","year":"2020","journal-title":"BMJ Open Quality"},{"key":"S0033291725100652_r21","unstructured":"Horowitz, M. , & Taylor, D. (2024). The Maudsley deprescribing guidelines in psychiatry: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs. https:\/\/scholar.google.com\/citations?view_op=view_citation&hl=en&citation_for_view=sEcbBuUAAAAJ:abG-DnoFyZgC"},{"key":"S0033291725100652_r42","unstructured":"Public Health England. (2019). Dependence and withdrawal associated with some prescribed medicines. An evidence review. https:\/\/www.gov.uk\/government\/publications\/prescribed-medicines-review-report"},{"key":"S0033291725100652_r20","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S2215-0366(24)00133-0","article-title":"Incidence of antidepressant discontinuation symptoms: A systematic review and meta-analysis","volume":"11","author":"Henssler","year":"2024","journal-title":"The Lancet Psychiatry"},{"key":"S0033291725100652_r3","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s11136-011-0031-4","article-title":"Reliability of adverse symptom event reporting by clinicians","volume":"21","author":"Atkinson","year":"2012","journal-title":"Quality of Life Research: an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation"},{"key":"S0033291725100652_r16","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.4088\/JCP.08m04548","article-title":"Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: A 24-week randomized, double-blind, placebo-controlled trial","volume":"70","author":"Goodwin","year":"2009","journal-title":"The Journal of Clinical Psychiatry"},{"key":"S0033291725100652_r55","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320967183","article-title":"The \u201cpatient voice\u201d: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition","volume":"10","author":"Guy","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"key":"S0033291725100652_r12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.addbeh.2018.08.027","article-title":"A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?","volume":"97","author":"Davies","year":"2019a","journal-title":"Addictive Behaviors"},{"key":"S0033291725100652_r7","unstructured":"Brody, D. , & Gu, Q. (2020, September 8). Antidepressant use among adults: United States, 2015\u20132018. Centers for Disease Control and Prevention Website. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db377.htm"},{"key":"S0033291725100652_r28","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1017\/S0033291700042008","article-title":"Long-term treatment of endogenous depression with nortriptyline with control of plasma levels","volume":"4","author":"Kragh-Sorensen","year":"1974","journal-title":"Psychological Medicine"},{"key":"S0033291725100652_r34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JCP.0b013e3181c8ae80","article-title":"Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome","volume":"30","author":"Murata","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"S0033291725100652_r38","article-title":"The myth that antidepressants are addictive has been debunked \u2013 they are a vital tool in psychiatry","author":"Pariante","year":"2024","journal-title":"The Guardian"},{"key":"S0033291725100652_r47","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41380-021-01285-w","article-title":"The relationship between dose and serotonin transporter occupancy of antidepressants-a systematic review","volume":"27","author":"S\u00f8rensen","year":"2022b","journal-title":"Molecular Psychiatry"},{"key":"S0033291725100652_r19","unstructured":"Health Research Authority. (2024). Safety and progress reports (other research) procedural table. Health Research Authority Website. https:\/\/www.hra.nhs.uk\/approvals-amendments\/managing-your-approval\/safety-reporting\/safety-and-progress-reports-other-research-procedural-table\/"},{"key":"S0033291725100652_r49","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/00004714-199606000-00005","article-title":"Paroxetine in the treatment of generalized social phobia: Open-label treatment and double-blind placebo-controlled discontinuation","volume":"16","author":"Stein","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"S0033291725100652_r4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1503\/jpn.130040","article-title":"Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: A phase III, randomized, double-blind, fixed-dose, placebo-controlled study","volume":"39","author":"Bakish","year":"2014","journal-title":"Journal of Psychiatry and Neuroscience: JPN"},{"key":"S0033291725100652_r22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40263-022-00960-y","article-title":"Estimating risk of antidepressant withdrawal from a review of published data","volume":"37","author":"Horowitz","year":"2023","journal-title":"CNS Drugs"},{"key":"S0033291725100652_r10","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/01.jcp.0000138767.53976.10","article-title":"Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder","volume":"24","author":"Cohen","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"S0033291725100652_r30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jclinepi.2019.04.020","article-title":"Harms are assessed inconsistently and reported inadequately part 2: Nonsystematic adverse events","volume":"113","author":"Mayo-Wilson","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"key":"S0033291725100652_r11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00004714-199808000-00017","article-title":"Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine","volume":"18","author":"Dallal","year":"1998","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"S0033291725100652_r1","doi-asserted-by":"crossref","first-page":"e0284389","DOI":"10.1371\/journal.pone.0284389","article-title":"Global trends in antidepressant, atypical antipsychotic, and benzodiazepine use: A cross-sectional analysis of 64 countries","volume":"18","author":"Alabaku","year":"2023","journal-title":"PLoS One"},{"key":"S0033291725100652_r31","doi-asserted-by":"crossref","first-page":"100765","DOI":"10.1016\/j.jadr.2024.100765","article-title":"The nature and impact of antidepressant withdrawal symptoms and proposal of the discriminatory antidepressant withdrawal symptoms scale (DAWSS)","volume":"16","author":"Moncrieff","year":"2024","journal-title":"Journal of Affective Disorders Reports"},{"key":"S0033291725100652_r37","volume-title":"Depression in adults: treatment and management: Guidance","year":"2022b"},{"key":"S0033291725100652_r36","volume-title":"Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults: Guidance","year":"2022a"},{"key":"S0033291725100652_r35","unstructured":"NHS Digital. (2023). Medicines used in Mental Health England 2022\/23. NHS Business Services Authority Website https:\/\/nhsbsa-opendata.s3.eu-west-2.amazonaws.com\/mumh\/mumh_annual_2223_v001.html"},{"key":"S0033291725100652_r53","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/WNF.0000000000000139","article-title":"Characteristics of Escitalopram discontinuation syndrome: A preliminary study","volume":"39","author":"Yasui-Furukori","year":"2016","journal-title":"Clinical Neuropharmacology"},{"key":"S0033291725100652_r17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/026988110101500210","article-title":"Antidepressant discontinuation (withdrawal) symptoms presenting as \u201cstroke\u201d","volume":"15","author":"Haddad","year":"2001","journal-title":"Journal of Psychopharmacology"},{"key":"S0033291725100652_r43","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1600-0447.2001.00263.x","article-title":"Sertraline treatment of panic disorder: Results of a long\u2010term study","volume":"104","author":"Rapaport","year":"2001","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"S0033291725100652_r25","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.addbeh.2019.01.025","article-title":"The war on antidepressants: What we can, and can\u2019t conclude, from the systematic review of antidepressant withdrawal effects by Davies and Read","volume":"97","author":"Jauhar","year":"2019","journal-title":"Addictive Behaviors"},{"key":"S0033291725100652_r50","first-page":"175","article-title":"SSRI and SNRI withdrawal symptoms reported on an internet forum","volume":"29","author":"Stockmann","year":"2018","journal-title":"The International Journal of Risk and Safety in Medicine"},{"key":"S0033291725100652_r5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S1461145705006358","article-title":"Discontinuation symptoms in depression and anxiety disorders","volume":"10","author":"Baldwin","year":"2007","journal-title":"The International Journal of Neuropsychopharmacology \/ Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum"}],"container-title":["Psychological Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0033291725100652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T07:01:37Z","timestamp":1753167697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0033291725100652\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":56,"alternative-id":["S0033291725100652"],"URL":"https:\/\/doi.org\/10.1017\/s0033291725100652","relation":{},"ISSN":["0033-2917","1469-8978"],"issn-type":[{"value":"0033-2917","type":"print"},{"value":"1469-8978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"\u00a9 The Author(s), 2025. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e191"}}